The road to treatment 17
The road to treatment 17 On our 5th anniversary, Guy Lenaers gave us a presentation about the work he and his colleagues do at the University of Angers (France). The team of Dr. Guy Lenaers, consisting of 60 experts (30 medical professionals and 30 researchers), specializes in hereditary mitochondrial diseases and has unique […]
The road to treatment 16
The Road to Treatment 16 In October we had the pleasure of speaking with Neurophth Therapeutics, a Chinese company developing a gene therapy for ADOA. Recently, Australia's Therapeutic Goods Administration (TGA) approved this program as a drug candidate for clinical investigation, which is necessary to test the drug in ADOA patients. A […]
The road to treatment 15
The Road to Treatment 15 Professor Marcela Votruba of Cardiff University in the United Kingdom, a researcher who discovered the link between ADOA and the damaged OPA1 gene, has spent years researching ADOA. Her research focuses on understanding the disease mechanism of autosomal dominant optic atrophy and designing therapies. […]
The road to treatment 14
The road to treatment 14 Interview with Professor Xian-Jie Yang of the Stein Eye Institute at the University of California, Los Angeles Would you like to tell us something about the background of your research? In October 2023 we had a conversation with Professor Xian-Jie Yang from the Stein Eye Institute at the University of California […]
The road to treatment 13
The road to treatment 13 On August 28, 2023, we had an online meeting with Professor Jeffrey Goldberg and Dr. Marius Wernig of Stanford University. This discussion revolved around the exciting potential of regeneration for various patient groups with optic nerve damage, including those affected by ADOA. With ADOA, damage […]
The road to treatment 12
The road to treatment 12 Report of meeting with Abeona Therapeutics by Peter Makai. Last summer we met with Abeona Therapeutics, a company working on a gene therapy to treat ADOA. In ADOA there is a genetic error in the so-called OPA1 gene, which is necessary for the functioning of the mitochondria in […]
The road to treatment 11
The road to treatment 11 In some patients, ADOA has developed significantly and a large part of the optic nerve cells have already died. This results in a vision loss of 5-10%. Fortunately, there are researchers trying to determine if it is possible to help patients with significant optic nerve cell loss. One of […]
The road to treatment 10
The road to treatment 10 Interview Cansu de Muijnck, by Maud van Gerwen (board member) Cansu is a PhD student and she is conducting PhD research into hereditary optic atrophies (including ADOA). She works with Camiel Boon, Arthur van Bergen and Mies van Genderen, all specialists in this field. Cansu is originally from Turkey and is four […]
The road to treatment 9
The road to treatment 9 In January 2024, an article was published about a study into red light therapy in children with high myopia. For completeness, we have added the results of the study. Low-level red light therapy (LLRL) has recently emerged as a treatment for myopia in children, […]
The road to treatment 8
The road to treatment 8 At the end of 2021, one of our contacts at Stoke Therapeutics sent us their financial results and business updates. It states, among other things (translated from their page): The company has nominated STK-002 as a clinical candidate for the treatment of ADOA, a serious and progressive disease of the optic nerve. There are currently no approved […]
